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Cellular Biology
MAPK Phosphorylation of Connexin 43 Promotes Binding
of Cyclin E and Smooth Muscle Cell Proliferation
Scott R. Johnstone, Brett M. Kroncke, Adam C. Straub, Angela K. Best, Clarence A. Dunn,
Leslie A. Mitchell, Yelena Peskova, Robert K. Nakamoto, Michael Koval, Cecilia W. Lo,
Paul D. Lampe, Linda Columbus, Brant E. Isakson
Rationale: Dedifferentiation of vascular smooth muscle cells (VSMC) leading to a proliferative cell phenotype
significantly contributes to the development of atherosclerosis. Mitogen-activated protein kinase (MAPK) phosphor-
ylation of proteins including connexin 43 (Cx43) has been associated with VSMC proliferation in atherosclerosis.
Objective: To investigate whether MAPK phosphorylation of Cx43 is directly involved in VSMC proliferation.
Methods and Results: We show in vivo that MAPK-phosphorylated Cx43 forms complexes with the cell cycle
control proteins cyclin E and cyclin-dependent kinase 2 (CDK2) in carotids of apolipoprotein-E receptor null
(ApoE/) mice and in C57Bl/6 mice treated with platelet-derived growth factor–BB (PDGF). We tested the
involvement of Cx43 MAPK phosphorylation in vitro using constructs for full-length Cx43 (Cx43) or the Cx43
C-terminus (Cx43CT) and produced null phosphorylation Ser>Ala (Cx43MK4A/Cx43CTMK4A) and phospho-
mimetic Ser>Asp (Cx43MK4D/Cx43CTMK4D) mutations. Coimmunoprecipitation studies in primary VSMC
isolated from Cx43 wild-type (Cx43/) and Cx43 null (Cx43/) mice and analytic size exclusion studies of
purified proteins identify that interactions between cyclin E and Cx43 requires Cx43 MAPK phosphorylation.
We further demonstrate that Cx43 MAPK phosphorylation is required for PDGF-mediated VSMC proliferation.
Finally, using a novel knock-in mouse containing Cx43-MK4A mutation, we show in vivo that interactions
between Cx43 and cyclin E are lost and VSMC proliferation does not occur after treatment of carotids with
PDGF and that neointima formation is significantly reduced in carotids after injury.
Conclusions: We identify MAPK-phosphorylated Cx43 as a novel interacting partner of cyclin E in VSMC and
show that this interaction is critical for VSMC proliferation. This novel interaction may be important in the
development of atherosclerotic lesions. (Circ Res. 2012;111:201-211.)
Key Words: connexin 43  phosphorylation  atherogenesis  platelet-derived growth factor
 vascular smooth muscle cells  proliferation  neointima
Vascular smooth muscle cell (VSMC) proliferation is amajor component of disease progression in atheroscle-
rosis and in its treatment, for example, after angioplasty and
in restenosis.1–3 In the earliest stages of atherosclerosis
(atherogenesis) VSMC dedifferentiate in response to athero-
genic stimuli, for example, oxidized phospholipids and
growth factors, such as platelet-derived growth factor–BB
(PDGF).4,5 Dedifferentiated VSMC increase atherosclerotic
plaque size by proliferating and migrating into the plaque,
followed by foam cell formation and senescence and through
ongoing cellular proliferation within the plaque.3,6,7 Treat-
ment of advanced plaques through angioplasty produces the
unwanted side effect of stimulating further VSMC prolifera-
tion, leading to neointima formation and significantly reduc-
ing the vessel lumen.6,8 Advanced plaques are composed of a
number of different cell types including macrophages and
foam cells derived from both monocytes and from VSMC
originating in the medial layers of arterial vessels.9–11 There-
fore, identifying the causes of VSMC proliferation becomes
central in the control of atherosclerosis and its treatments.
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Several lines of evidence suggest that connexins (Cx) play a
key role in the regulation of atherosclerotic disease progression
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and VSMC proliferation in particular Cx43, which has a role in
cellular proliferation.12–16 Connexins typically form gap junc-
tions through a dodecameric association of connexin proteins
that produces a functional channel between 2 cells that allows
for coordinated cellular responses. Changes in the expression
levels of Cx43 have been associated with VSMC proliferative
potential in atherogenesis, in atherosclerotic plaque development
and in restenosis.12,15,17 In addition, multiple studies have now
demonstrated that Cx43 can modulate cellular proliferation in a
manner that is independent of gap junctional communica-
tion.18–21 However, the exact pathways through which Cx43
modulates cellular proliferation are not known.
Activation of mitogen-activated protein kinase (MAPK)
pathways promotes VSMC proliferation in atherogenesis.22
Many proatherogenic agents (eg, PDGF) have been shown to
activate MAPK pathways, yet the mechanisms through which
these pathways induce VSMC proliferation are poorly de-
fined.5 Several lines of evidence indicate that MAPK phos-
phorylation of Cx43 can occur at specific C-terminus (CT)
residues, for example, S255/S262/S279/S282, and occurs
differentially throughout the cell cycle.23–27
Recently, we identified that Cx43 becomes phosphorylated
at its MAPK serines in response to atherogenic stimuli and
that this is associated with VSMC proliferation both in vivo
and in vitro.12 We demonstrate from the single protein level
to whole mouse that Cx43 mediates its control over VSMC
proliferation through an interaction of its C-terminus with the
cell cycle control protein cyclin E in a manner that is
dependent on Cx43 MAPK phosphorylation.
Methods
An expanded Methods section is available in the Online Data
Supplement.
Mice
C57/Bl6 (10–18 weeks), ApoE/ (15–18 weeks), and novel Cx43-
MK4A (10–18 weeks) mice were used according to the University of
Virginia Animal Care and Use Committee guidelines.
Electron Microscopy
Carotid arteries were imaged for VSMC morphology and immuno-
labeled using Cx43, cyclin E, or CDK2 antibodies and detected with
25/15/10 nm gold beads, respectively, and imaged using a JEOL
6400 scanning electron microscope.
Plasmids and Mutagenesis
Derivatives of pCDNA3.1 and pGEX-6P-2 for expression of full length
Cx43 (Cx43, a.a.1–382, pCDNA3.1), the Cx43 C-terminus (Cx43CT,
rat, a.a. 236–382, pCDNA3.1, and pGEX-6P-2), and for full-length
human cyclin E (pGEX-6P-2) were used. Mutagenesis of Cx43 MAPK
serines to either alanines or aspartates was performed by Quickchange
(Strategene). Plasmids were used for in vitro transfection or analysis of
protein interaction by analytic size exclusion chromatography.
Statistical Analysis
Student t test, 1-way ANOVA, or 2-way ANOVA, followed by
Bonferroni posttest, were used for comparisons between treatments.
A probability value of 0.05 was significant.
Results
Cx43 Colocalizes With Cyclin E in VSMC
and In Vivo
To test whether Cx43 protein expression and its posttranslational
modification are linked to VSMC proliferation, we initially
screened potential binding partners of Cx43 that are associated
with the G1 phase of the cell cycle including cyclin E, cyclin D1,
p21waf1cip1, and p27kip1. Coimmunoprecipitation studies identi-
fied that Cx43 associated with cyclin E but not the other proteins
tested (Online Figure V). We therefore tested the ability of Cx43
to interact with cyclin E in vivo by immunofluorescence on
carotid vessel sections. We identified marked increases in
protein expression for both Cx43 and cyclin E within the carotid
VSMC after PDGF treatment as compared with control condi-
tions (Figure 1A). Using the proximity ligation assay, we further
demonstrated almost no detectable interactions between of Cx43
and cyclin E under control conditions but significant increases in
interaction after PDGF treatments (Figure 1B). To determine the
spatial interaction between the proteins in vivo we analyzed
colocalization between Cx43, cyclin E, and CDK2 by immune-
transmission electron microscopy (i-TEM; Figure 1C). Under
control conditions, interactions were not identifiable between
Cx43 and cyclin E or CDK 2 in carotid VSMC [ie, large average
distance between beads of 49070 nm (Cx43-cyclin E) and
37972 nm (Cx43-CDK2; Figure 1D) were observed]. In
VSMC of carotids from PDGF-treated mice and in ApoE/
mice (containing proliferative VSMC),12 significant reductions
in distances between Cx43-cyclin E, Cx43-CDK2, and cyclin
E–Cx43-CDK2 were identified with distance averaging 10 to 20
nm, indicative of interaction between the proteins (Figure 1D).
Under control conditions, Cx43 MAPK phosphorylation was not
readily detectable, with too few beads present as to be quantified
on all sections (Figure 1E). However, treatments with PDGF and
in ApoE/ mice (as described)12 increased Cx43 MAPK
phosphorylation, and interactions were identified with cyclin E
and CDK2 (Figure 1E).
Cx43 Coprecipitates With Cyclin E and
CDK2 In Vitro
To further investigate the interaction between Cx43, cyclin E,
and CDK2, we isolated aortic VSMC from newborn mice
Non-standard Abbreviations and Acronyms
CBX carbenoxolone
CDK2 cyclin-dependent kinase 2
CT C-terminus
Cx connexin
ERK extracellular signal-regulated protein kinase
GST glutathione S-transferase
i-TEM immune-transmission electron microscopy
MAPK mitogen-activated protein kinase
MK4A Map kinase 4 alanine mutation
MK4D Map kinase 4 aspartate mutation
PDGF platelet-derived growth factor–BB
pRb phosphorylated retinoblastoma
Rb retinoblastoma
TEM transmission electron microscopy
VSMC vascular smooth muscle cell
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(Cx43/; Online Figure II). Increases in Cx43, cyclin E, and
CDK2 protein expression and coimmunoprecipitation of Cx43
with cyclin E and CDK2 proteins were identified after 24-hour
treatments with PDGF (Online Figure VI). To define the cellular
compartment of protein interaction and to identify the temporal
relationship between Cx43 and cyclin E interactions, we inves-
tigated protein expression levels and coimmunoprecipitation by
Western blot in total proteins lysates and membrane fractions of
Cx43/ VSMC. After PDGF treatments, expression of Cx43,
MAPK-phosphorylated Cx43 (Cx43-P), and cyclin E all in-
creased after 6 hours of treatment with PDGF in total protein
lysates, with increases in CDK2 observed from 12 hours (Figure
2A). In membrane fractions, expression of Cx43, Cx43-P, and
cyclin E increased between 6- to 12-hour time points, after
which marked reductions were observed (Figure 2A). Coimmu-
noprecipitation studies demonstrated that Cx43 and cyclin E
form in complex by 12 hours in membrane fractions and were
detectable at both 12 and 24 hours in total protein lysates (Figure
2A). To determine the effects on downstream targets of cyclin E
and CDK2 activation, we performed Western blots of retino-
blastoma (Rb) protein expression and its phosphorylation (pRB).
After PDGF treatments, we identified in Rb protein expression,
and phosphorylation (pRb-780 and pRb-807/811) was increased
between 12 to 24 hours after PDGF treatments (Figure 2B). To
define whether MAPK phosphorylation of Cx43 was critical in
this interaction, Cx43/ VSMC gown in low serum media
were pretreated with extracellular signal-regulated protein kinase
(ERK) inhibitors U0126 or Roscovitine followed by PDGF
treatment. Both U0126 and Roscovitine inhibited the ability of
Cx43 to become phosphorylated at MAPK serines and inhibited
interactions with cyclin E and corresponded to significant
reductions in VSMC proliferation (Figure 2C). Using Cx43/
cells treated with PDGF in the presence of U0126 or Roscovi-
tine, we saw significant reductions in VSMC proliferation,
indicating that MAPK phosphorylation of Cx43 is important in
the proliferative phenotype of VSMC in response to PDGF
(Figure 2C).
Cx43 Interactions With Cyclin E Are Controlled
Through MAPK Phosphorylation
To further examine the role of Cx43 MAPK phosphorylation,
VSMC were isolated from aortas of newborn Cx43/,
Figure 1. In vivo colocalization of Cx43
and cell cycle proteins. Representative
immunofluorescence images show carotid
vessels from control or PDGF-treated
C57Bl/6 mice (A and B). Immunofluores-
cence of Cx43 (red) and cyclin E (green),
with blue indicating nuclei (DAPI); asterisk
indicates the luminal side of the vessels,
and the scale bar is 20 m. A, Immuno-
fluorescent colocalization of proteins is
demonstrated by orange staining (overlay
of green and red staining) in each section.
B, Immunofluorescence, proximity ligation
assay for Cx43 and cyclin E, where red
staining indicates colocalization of the
proteins within 40 nm of each other. In B,
autofluorescence of the internal elastic
lamina (IEL, green) and nuclei (blue);
asterisk indicates the luminal side of the
vessels and the scale bar is 20 m.
Immune-TEM with expanded view (red
box) of a control carotid taken from a
C57Bl/6 mouse (C). The nucleus (Nuc),
smooth muscle cell (SMC), IEL, endotheli-
al cell (EC), and red blood cells (RBC) are
identified. In C, the red box highlights the
larger 25-nm beads labeling Cx43 (yellow
arrowhead) and 15-nm beads for cyclin E
(red arrowhead) in VSMC layers; bar rep-
resents 2 m. Representative higher mag-
nification iTEM images in D and E of
carotids taken from control or PDGF-
treated C57Bl/6 or ApoE/ mice immu-
nodetected for Cx43 or Cx43-P (as
labeled, 25-nm gold beads, yellow arrow-
head), cyclin E (polyclonal, 8–10-nm gold
beads, red arrowhead), or CDK2 (mono-
clonal, 15-nm beads, green arrowhead).
Colocalization demonstrated in represen-
tative images by the blue arrows. In the
corresponding graphs, average distances
between beads are shown as Cx43 to
cyclin E (red bars) or Cx43 and CDK2
(green bars) or blue bars, where interac-
tions are being measured for control (Con), PDGF (PD), or ApoE/ (Apo) mice. In E, Cx43-P expression is only shown for PDGF and
ApoE/ mice as it is not detected in controls; therefore no statistical significance was determined. In D and E, triple asterisk indicates
P0.001 as compared with controls (n20 interactions); the scale bar is 200 nm.
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Cx43/, or Cx43/ mice (Figure 3A), and we generated
plasmids with mutations at the 4 C-terminus MAPK serines
(S255/262/279/282) to mimic constitutive phosphorylation
(Cx43MK4D) or null phosphorylation (Cx43MK4A) (Figure 3B
and Online Figure IV). These plasmids were transfected into
Cx43/ VSMC at nearly equivalent levels (Figure 3C). Dye
transfer studies in control and PDGF-treated VSMC transfected
with the different plasmids showed no significant differences in
gap junctional communication (Online Figure VII). Pretreatment
of Cx43/ VSMC with the gap junction inhibitor carbenox-
olone (CBX) reduced gap junctional communication but did not
significantly reduce cellular proliferation in response to PDGF
treatments (Online Figure VII) Coimmunoprecipitation studies
from transfected Cx43/ VSMC treated with PDGF identified
that interactions with cyclin E only occurred with Cx43
and Cx43MK4D and not in Cx43MK4A (Figure 3D and
Online Table I).
To show that Cx43 C-terminus specifically binds cyclin E,
we generated and used purified Cx43 C-terminus and gluta-
thione S-transferase (GST)-tagged cyclin E proteins and
evaluated complex formation using analytical size exclusion
chromatography (Figure 3E and 3F). Individually, Cx43
C-terminus proteins (17 kDa; monomer) eluted in the same
fractions (16–19) and cyclin E (75 kDa) eluted in fractions
15 to 17 (Figure 3F). In all experiments, we did not detect
significant alterations in either the Cx43CT or the
Cx43CTMK4A proteins when combined with cyclin E (Fig-
ure 3F). However, after incubation of Cx43CTMK4D pro-
teins with cyclin E, we identified a marked shift in both
Cx43CTMK4D and cyclin E. Both proteins coeluted earlier in
the elution profile (fractions 14–17; increase in size), in-
dicating complex formation of Cx43CTMK4D with cyclin E
(Figure 3F). By cross-linking proteins in solution of fraction 15
from Cx43CTMK4D with cyclin E samples, we identified high-
molecular-weight forms of both Cx43 C-terminus and cyclin E
at110 kDa by Western blot, corresponding to a stoichiometry
of a single cyclin E and Cx43CTMK4D in dimer form (109 kDa;
Figure 3G).
Figure 2. In vitro identification of Cx43 colocalization with cell cycle proteins. Total protein and membrane fraction lysates from Cx43/
VSMC grown in low serum and treated with PDGF harvested were at specific time points over a 24-hour time course. Samples were ana-
lyzed by Western blot with antibodies against Cx43, Cx43-P, cyclin E, CDK2, GAPDH, or -tubulin and by coimmunoprecipitation with cyclin
E–coated beads and detection of Cx43 by Western blot (A). Specificity of Western blot detection is shown using antibody-coated beads
treated with lysis buffer only to eliminate IgG contamination (A). Expression of Rb, phosphorylated retinoblastoma (pRb)-780, and pRb-807/
811 were detected in total protein and membrane fraction lysates from PDGF time course experiments (B). Total protein lysates from
Cx43/ VSMC grown in low serum, pretreated with ERK inhibitors (U0126 and Roscovitine) or DMSO, then treated with PDGF for 24 hours
were analyzed by Western blot with antibodies against Cx43, Cx43-P, cyclin E, or CDK2 and by coimmunoprecipitation with cyclin E–coated
beads and detection of Cx43 by Western blot (C, top). VSMC proliferation of Cx43/ VSMC grown in low serum, pretreated with ERK inhib-
itors (U0126 and Roscovitine) or DMSO, then treated with PDGF for 24 hours was assayed by flow cytometry (C, bottom). In A through C,
black arrowheads identify the expected molecular weight for each protein; colored arrowheads correspond to molecular weights: green is 25
kDa, blue is 37 kDa, red is 50 kDa, yellow is 100 kDa. In C, triple asterisk indicates P0.001, n4.
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Based on the observations using purified proteins, we aimed
to determine whether expressing the free Cx43 C-terminus in
VSMC would lead to binding of cyclin E and alterations in
cellular proliferation. We therefore transfected Cx43/ VSMC
with plasmids to express Cx43CT, Cx43CTMK4A, and Cx43CTMK4D
proteins (Online Figure VIII). All 3 proteins were found to be
expressed in the transfected VSMC but did not form interactions
with cyclin E and did not confer increased VSMC proliferation
in response to PDGF treatment (Online Figure VIII). We further
determined that while all Cx43 C-terminus proteins were ex-
pressed, they did not traffic to the cellular membranes unlike full
length Cx43 proteins when transfected to Cx43/ VSMC
(Online Figure VIII).
VSMC Proliferation Is Controlled Through
MAPK Phosphorylation of Cx43
To identify a potential functional consequence of Cx43-
cyclin E interaction, we compared proliferation in Cx43/,
Cx43/, and Cx43/ VSMC grown in low serum media in
response to PDGF stimulation. Flow cytometric analysis indi-
cated that low serum induced a cell cycle stall (approximately
5% proliferation) in all cells. However, loss or reductions of
Cx43 (Cx43/, Cx43/, respectively) significantly ablates
PDGF-induced VSMC proliferation as compared with Cx43/
cells (Figure 4A). Western blot analysis of cyclin E and CDK2
expression in Cx43/ VSMC demonstrate that PDGF does not
induce marked increases in cyclin E expression; however,
Figure 3. Cx43 interactions with cyclin E are dependent on MAPK phosphorylation in vitro. The expression of vascular connexins
Cx43, Cx37, and Cx45 in VSMC isolated from newborn mouse aortas was identified by Western blotting (A). Site-directed mutagenesis
was performed for the MAPK sites in both full-length Cx43 (a.a.1–382) and Cx43CT (a.a. 236–382) for phosphomimetic (Aspartate, Cx43MK4D,
Cx43CTMK4D) and null phosphorylation (Cx43MK4A, Cx43CTMK4A) constructs (B). Primary VSMC from Cx43/ mice were transfected with
Cx43 plasmids and expression confirmed by Western blotting of Cx43 (C). Levels of expression were quantified against loading for GAPDH
(n3, C). Lysates from Cx43/ VSMC transfected with each of the Cx43 plasmids and treated with PDGF were incubated with cyclin
E–coated beads, then protein detection performed by Western blot analysis of Cx43 (n3, D). Cx43CT-GST and cyclin E1–GST proteins were
purified by GST bead purification followed by cleavage (Cx43CT proteins only) or elution (glutathione, cyclin E only). Samples were further
purified to 90% purity by size exclusion chromatography (SEC) with Cx43CT detected at approximately 17 kDa and cyclin E at 75 kDa due
to the addition of the 25-kDa GST tag (E). Purified proteins for Cx43CT, Cx43CTMK4A, Cx43CTMK4D, and cyclin E were assessed for in vitro
binding via analytical size exclusion chromatography either as solo proteins or in combination (Cx43CTcyclin E). Eluted fractions were ana-
lyzed for the expression of Cx43 (Cx43) or cyclin E (polyclonal) by Western blotting (n2, F). After analytical size exclusion chromatography
analysis, samples from elution fraction 15 from the Cx43CTMK4Dcyclin E samples were cross-linked using BS3 followed by Western blot
analysis (G). In C through E, black arrowheads identify the expected molecular weight for each protein; colored arrowheads correspond to
molecular weights: green is 25 kDa, blue is 37 kDa, red is 50 kDa, yellow is 100 kDa.
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CDK2 protein expression was increased by 24 hours in the
absence of Cx43 expression (Online Figure IX). Transfection of
Cx43/ VSMC with each the Cx43 plasmids followed by
treatment with PDGF produced a restoration of cell proliferation
in cells expressing both Cx43 and the Cx43MK4D proteins but not
the Cx43MK4A protein (Figure 4B).
Loss of MAPK Phosphorylation of Cx43 In Vivo
Reduces Interactions With Cyclin E and
VSMC Proliferation
To investigate the in vivo effects of Cx43 phosphorylation on
VSMC proliferation in vivo, we generated a novel knock-in
mouse line containing alanine mutation for Cx43 MAPK sites
(Cx43-MK4A; Online Figure I) that displays similar levels
of Cx43 expression to C57Bl/6 mice (Online Figure X). In the
Cx43-MK4A mice, Cx43 phosphorylation was not detected
either under control or PDGF-treated conditions, with in-
creases in C57Bl/6 shown (Figure 5A). Analysis by transmis-
sion electron microscopy (TEM) and through expression of
SM-actin by immunofluorescence revealed that PDGF treat-
ment did not produce any apparent phenotypic alterations in
the carotid VSMC of Cx43-MK4A mice, in contrast to those
that were identifiable in C57Bl/6 carotid VSMC (Figure 5B
and Online Figure X). Analysis of protein colocalization in
Cx43-MK4A mice in vivo using i-TEM and immunofluores-
cence identified a loss of interaction between Cx43 and cyclin
E or CDK2 in PDGF-treated carotid VSMC of Cx43-MK4A
mice (Figure 5C and Online Figure XI). Treatment of
C57Bl/6 mouse carotids with PDGF produced significant
increases in VSMC proliferation (20.44.4%), but there was
no evidence of VSMC proliferation in Cx43-MK4A mice
treated with PDGF (Figure 5D).
Loss of MAPK Phosphorylation of Cx43 In Vivo
Reduces Neointima Formation
To determine whether phosphorylation of Cx43 plays a
significant role in neointimal formation, we performed ca-
rotid ligation (injury) assays that have been previously
demonstrated to produce neointima formation in wild-type
mice.28 Carotids from ligated C57Bl/6 mice demonstrated
significant development of neointima, reduced luminal diam-
eter, and reductions in expression of SM-actin in media
VSMC that was not identified in Cx43-MK4A mice (Figure
6A through 6C and Online Figure III). Increases in both Cx43
and MAPK-phosphorylated Cx43 were identified in both the
media and neointima layers of C57Bl/6 mice but not within in
the media layers of Cx43-MK4A mice (Figure 6D and 6E).
Discussion
A common factor in the promotion of VSMC proliferation is
phosphorylation of proteins through activation of MAPK
pathways.29 We recently identified that MAPK phosphoryla-
tion of Cx43 correlates to VSMC proliferation in ApoE/
mice.12 In the present study, we identify that in response to
atherogenic stimuli, that is, PDGF and vascular injury, for
example, carotid ligation, Cx43 is phosphorylated at its
C-terminus MAPK residues (S255/S262/S279/S282)23 and that
this is a key regulator of VSMC proliferation and neointima
formation in vivo. We further demonstrate that the mechanism
underlying the proliferative response depends on a direct inter-
action of the Cx43 C-terminus with the cell cycle control protein
cyclin E. These results are summarized in Online Figure XII.
Vascular smooth muscle cell proliferation in atherogenesis
has been linked with an increase in the expression of PDGF.5
It has also been shown that PDGF stimulation increases the
expression of cyclin E, cyclin D1, and their associated
kinases (ie, CDK2 and CDK4), all of which are positive
regulators of cellular proliferation.30–33 In addition, PDGF
alters the expression levels of Cx43 which has been linked to
enhanced VSMC proliferation.14 In keeping with these stud-
ies, we identified increases in Cx43, cyclin E, and cyclin D1
in VSMC in response to PDGF treatments in vitro. Using
proliferative VSMC (10% serum), we found that Cx43 forms
interactions with cyclin E but not with cyclin D1 or the cell
cycle inhibitors p21waf1/cip1 or p27kip1. Treatment of VSMC
with PDGF induced MAPK phosphorylation of Cx43 and
promoted formation of Cx43 complexes with cyclin E and its
associated kinase CDK2. Complexes between MAPK-phos-
phorylated Cx43 with cyclin E and CDK2 were also identi-
fied in PDGF-treated C57Bl/6 and in ApoE/ mice, as
demonstrated through proximity ligation and i-TEM in vivo.
These data indicate that Cx43 may act to interact with
specific cell cycle proteins in proliferative VSMC.
Figure 4. Cx43 MAPK phosphorylation
is critical in VSMC proliferation in vitro.
VSMC isolated from Cx43/, Cx43/,
and Cx43/ mice were grown in low
serum media for 72 hours, then treated
with EDU (control) or EDUPDGF (PDGF)
and VSMC proliferation measured as a
percentage of total cells via flow cytom-
etry (A). Cx43/ VSMC were transfected
with controls (lipofectamine and empty
vector) or with the Cx43 plasmids (Cx43,
Cx43MK4A, Cx43MK4D). Cells were then
treated with EDUPDGF and VSMC pro-
liferation measured as a percentage of
total cells via flow cytometry (B). In
graphs, asterisk indicates P0.05, dou-
ble asterisk indicates P0.01, and triple
asterisk indicates P0.001 (A, n6; B,
n3).
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Whereas cyclin E is ubiquitously expressed in cells,
formation of active complexes with CDK2 occur at the cell
membrane and is followed by removal of the complex from
the cell membrane.34 Accumulation of cyclinE-CDK2 com-
plexes in s-phase of the cell cycle can be further regulated by
MAPK activation.35 In our studies, we identified that PDGF
temporally increases global expression of Cx43, Cx43-P,
cyclin E, and CDK2 proteins over a 24-hour period and that
Cx43 and cyclin E protein expression increased transiently in
membrane fractions with marked reductions found between
12 to 24 hours. We further show that Cx43-cyclin E com-
plexes were present at 12 hours in membrane fractions and in
total protein isolates between 12 to 24 hours. Increases in
Cx43-cyclin E binding corresponded to an increase in the
expression and phosphorylation of Rb, a downstream target
of the cyclin E-CDK2 complex that acts to promote cellular
proliferation.36 Activation of MAPK pathways, for example,
ERK1/2, after increased PDGF expression promotes a prolif-
erative phenotype in VSMC.37,38 After treatments with known
ERK pathway inhibitors, for example, U0126 and CDK2
inhibitor roscovitine,35 we show that interactions between
Cx43 and cyclin E can be inhibited and VSMC proliferation
significantly reduced. Expression of free Cx43CT proteins
within Cx43/ VSMC cells failed to produce an interaction
Figure 5. MAPK phosphorylation of
Cx43 is critical in VSMC proliferation in
vivo. Representative immunofluorescence
images from control and PDGF-treated
carotids from C57Bl/6 and Cx43-MK4A
mice (A). Phosphorylated Cx43 protein
expression (Cx43-P) after PDGF treat-
ments was analyzed by immunofluores-
cence (A). In each image, red represents
Cx43-P, green represents autofluores-
cence from the internal elastic lamina,
blue indicates nuclei (DAPI), and asterisk
represents the luminal side of the vessels;
scale bar is 20 m. In B (top), electron
micrographs show the ultrastucture of
VSMC layers in the carotids from C57Bl/6
and Cx43-MK4A mice under control or
PDGF-treated conditions; scale bar is
2 m. SM-actin (SM-22) protein expres-
sion after PDGF treatments was analyzed
by immunofluorescence (B, bottom). In
each image, magenta represents SM22-
and blue indicates nuclei (DAPI); asterisk
represents the luminal side of the vessels;
scale bar is 20 m. In C, representative
i-TEM images of carotid VSMC from con-
trol or PDGF-treated Cx43-MK4A mice
show Cx43 (Cx43, 25-nm gold beads, yel-
low arrows), cyclin E (polyclonal, 8–10-nm
gold beads, red arrows), or CDK2 (mono-
clonal, 15-nm beads, green arrows). In the
corresponding graphs, average distance
between beads are shown as Cx43 to
cyclin E (red bars) or Cx43 to CDK2
(green bars). No colocalization was dem-
onstrated for control (Con) or PDGF ves-
sels. In vivo cell proliferation measured
EDU incorporation (red) in the nuclei (blue,
DAPI) of C57Bl/6 and Cx43-MK4A mice
under control or PDGF-treated conditions.
Proliferation of VSMC was measured as
the number of nuclei incorporating EDU
as compared with total nuclei counted
(n4, D). In D, triple asterisk indicates
P0.001 as compared with controls.
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with cyclin E and failed to elicit PDGF induced proliferation
as can be seen for the full-length protein. In keeping with
previous reports that expression of the free Cx43CT leads to a
diffuse pattern of staining within cells and does not affect
cellular proliferation,39 we further show that the free Cx43CT
does not target the cell membrane, suggesting that mem-
brane localization is a key component in the interaction
between Cx43 and cyclin E. However there are previous
reports that the free Cx43CT protein expressed in HeLa
cells can inhibit cellular proliferation although the path-
ways associated with this have not been clearly demon-
strated.40 These data indicate that PDGF induces prolifer-
Figure 6. MAPK phosphorylation is required for neointima formation after carotid injury. Cross sections from C57Bl/6 and Cx43-
MK4A mice under control or injury conditions were stained by hematoxylin and eosin for analysis of neointima formation (A). Expres-
sion of smooth muscle actin (SM22-, magenta) was detected in media and neointima layers by immunofluorescence (B). Measures for
the areas corresponding to neointima and media layers were used to calculate the ratio in control and injured C57Bl/6 and Cx43-MK4A
mice (C, n7). Immunofluorescent detection of Cx43 (D) and Cx43-P (E) in control and injured C57Bl/6 and Cx43-MK4A mice is
shown. Scale bars in A, B, D, and E are 50 m. In C, asterisk indicates P0.05; double asterisk indicates P0.01.
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ation in VSMC through a mechanism that involves binding
of MAPK-phosphorylated Cx43 to cyclin E and that
formation of a complex between Cx43 and cyclin E
initiates at the membrane and is followed by an internal-
ization of the complex which promotes retinoblastoma
phosphorylation and cell cycle progression.
It has previously been shown that PDGF increases Cx43
expression levels but that PDGF-induced MAPK phosphor-
ylation of Cx43 reduces gap junction permeability leading to
the hypothesis that gap junctional signaling pathways may
contribute regulation of VSMC proliferation.41–43 Similar
studies identified that truncation of Cx43 C-terminus (a.a.
256) significantly reduces the PDGF-induced response, po-
tentially indicating that gap junctional communication is
involved but also suggest that there may also be a connexin
mediated (but non–gap junctional) component to PDGF-
associated cell cycle regulation.44,45 In agreement with these
studies, we find that a loss or reduction of Cx43 expression in
Cx43/ and Cx43/ VSMC (respectively) correlates to
significant reductions in the PDGF-induced proliferative
response. We also demonstrate a rescue of the proliferative
response in Cx43/ VSMC transfected to express Cx43 and
Cx43MK4D. Despite this, levels of gap junction communica-
tion were not significantly altered in the Cx43/ VSMC as
compared with Cx43/ VSMC. A reduction in dye transfer
was observed in Cx43/ after treatment with CBX indicating
that gap junctional communication does occur within Cx43/
VSMC. The identification of dye transfer in Cx43/ cells
suggests that they are still functionally coupled potentially
through the remaining Cx37 and Cx45 identified within the
cells. However, treatments with CBX failed to significantly
reduce VSMC proliferation suggesting that proliferation can
occur in a manner that is independent of gap junctional commu-
nication. Additionally, when Cx43/ VSMC were transfected
to express Cx43, the null phosphorylation (Cx43MK4A) or the
phospho-mimetic (Cx43MK4D) forms, gap junctional communi-
cation was not significantly altered. However, in Cx43/
VSMC transfected to express Cx43MK4A, the interaction be-
tween Cx43 and cyclin E was lost and there was no return to
proliferation. Conversely, Cx43/VSMC expressing Cx43 and
Cx43MK4D demonstrate formation of Cx43-cyclin E complexes
and a return to proliferation in response to PDGF. Taken
together, these data suggest that in response to PDGF, Cx43
becomes phosphorylated at its MAPK serines and interacts with
cyclin E, which, in turn, promotes VSMC proliferation in a
manner that is independent of gap junctional communication.
Despite this, PDGF treatments did not significantly reduce gap
junction communication in our cells, and this leaves the possi-
bility that a role for gap junctions does exist in these pathways.
To confirm our findings, we generated a novel knock-in
mouse (Cx43-MK4A) that contains the Cx43 MAPK serine
to alanine substitution expressed on the endogenous promoter
for Cx43. In the Cx43-MK4A mice, we found levels of Cx43
expressed in carotid VSMC were similar to C57Bl/6 mice and
showed that under control and PDGF-treated conditions there
was no evidence for Cx43 MAPK phosphorylation in the
Cx43-MK4A mice. Although Cx43 was present in the VSMC
as well as cyclin E and CDK2, we could not identify
interactions between Cx43 and cyclin E or Cx43 and CDK2.
This finding is consistent with a requirement for Cx43 MAPK
phosphorylation in forming interactions with cyclin E. In
addition, we demonstrated a lack of VSMC proliferation in
Cx43-MK4A mice and did not observe phenotypic changes
in VSMC as identified in C57Bl/6 mice in response to PDGF
treatment. In response to vascular injury, VSMC dedifferen-
tiate and migrate to the intima of the vessel producing the
neointima.28,46,47 Previous studies have demonstrated that
Cx43 expression is significantly enhanced in the medial and
neointimal VSMC after vascular injury.14–16,48 Development
of neointima has been associated to MAPK phosphorylation
and to alterations in cyclins and CDK pathways and can be
significantly inhibited through treatments with inhibitors of
MAPK, pathways pathways.49–51 After vascular injury in
C57Bl/6 mice, we demonstrate significant formation of neo-
intimal lesions, derived from VSMC (SM-22 positive). In
keeping with previous studies, we demonstrate that Cx43
expression as well as MAPK-phosphorylated Cx43 is in-
creased in media and neointimal VSMC in C57Bl/6 mice.
However, in Cx43-MK4A mice vascular injury failed to
produce significant neointimal formation. Previous studies by
others have demonstrated contrasting roles for Cx43 in
neointimal formation, with conditional VSMC knockout of
Cx43 promoting neointimal formation52 and conversely by
others suggesting that reduced Cx43 expression can limit
neointimal formation.17 In each of these models, a number of
factors could contribute to differences between results includ-
ing incomplete knockdown of Cx43 in the conditional knock-
out mouse52 or compensation by other connexins within the
Cx43/ mice as well as differences in model systems, for
example, high-fat fed.17 These conflicting results, however,
clearly demonstrate the complex nature of Cx43 in regulating
VSMC proliferation in response to vascular injury. In com-
parison to previous models, our Cx43-MK4A mice maintain
levels of Cx43 expression within the VSMC of carotids and
demonstrate specifically attenuated the neointima formation
suggesting that Cx43 is critical in the regulation of neointimal
formation. Our data therefore demonstrate that MAPK phos-
phorylation of Cx43 serines critically regulate VSMC dedif-
ferentiation, proliferation, and neointima formation in vivo.
Our studies demonstrate that Cx43 interacts with cyclin E in
a manner that is dependent on MAPK phosphorylation of the
Cx43 C-terminus. Previous studies by others have shown that
the C-terminus of Cx43 can interact with a number of proteins
including tubulin and zonula occludens-1, which are associated
with targeting of Cx43 at the plasma membrane.53–55 Further
studies have also shown the potential for interactions between
the C-terminus of Cx43 and proteins that regulate cell cycle, for
example, NOV and SKP2.19,21,56 To define the region on Cx43
where interaction with cyclin E occurs, we generated and
purified proteins for the full-length cyclin E and for the Cx43
C-terminus including the null phosphorylation and phospho-
mimetic forms. We identified that only Cx43CTMK4D proteins
formed interactions with cyclin E. In this in vitro system, we saw
no evidence for cyclin E interactions with the native state
Cx43CT or the Cx43CTMK4A. By cross-linking proteins in
solution from the Cx43CTMK4D samples, we identified higher-
molecular-weight forms of both cyclin E and Cx43 at approxi-
mately 110 kDa by Western blot. This corresponds to a complex
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containing a single cyclin E–GST and a dimer of Cx43. This
finding is consistent with previous findings that Cx43 is required
to be in a dimeric form to interact with known binding part-
ners.57 In addition to this, we saw no evidence for interaction at
higher pH values (pH 7.4, data not shown), where Cx43 is
primarily in monomeric forms and is consistent with previously
published data.57 Taken together, these data suggest that inter-
actions between MAPK-phosphorylated Cx43 and cyclin E
occur within the C-terminus of Cx43 and require the presence of
these phosphorylation sites and that these interactions can occur
outside of PDGF stimulation in VSMC.
In conclusion, our studies have demonstrated 3 key con-
clusions: (1) that Cx43 specifically interacts with the cell
cycle protein cyclin E in a manner that is dependent on
MAPK phosphorylation; (2) that MAPK-phosphorylated
Cx43 promotes VSMC proliferation in response to PDGF
treatments; and (3) that after vascular injury, MAPK-phos-
phorylated Cx43 can significantly regulate neointimal forma-
tion. Further studies on this interaction may lead to a novel
target for therapeutic intervention in the development athero-
sclerosis and restenosis.
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Novelty and Significance
What Is Known?
● A change in smooth muscle cells from nonproliferative (eg, normal) to
proliferative (eg, diseased) states is regulated by mitogen-activated
protein kinase pathways (MAPK).
● Alterations in Cx43 protein expression are associated with changes in
smooth muscle cells to a proliferative phenotype.
What New Information Does This Article Contribute?
● Cx43 directly interacts with the cell cycle control protein cyclin E.
● Cx43–cyclin E interactions are dependent on the MAPK phosphory-
lation of Cx43.
● Interactions between Cx43 and cyclin E are critical determinants in
smooth muscle cell proliferation and neointimal formation in vivo.
Atherosclerosis has one of the highest mortality rates in the
United States, with dysregulated smooth muscle cell prolifera-
tion being a hallmark of the disease. Connexin 43 (Cx43) has
previously been associated with regulation of cellular prolifera-
tion, although the mechanisms have not been described. We
identified direct protein interactions between Cx43 and cyclin E,
a protein that regulates how cells divide. We specifically
demonstrate that phosphorylation of Cx43 protein by MAPK is
required for it to bind to cyclin E. Using novel mice in which Cx43
cannot be phosphorylated by MAPK, we further show that this
interaction is a critical determinant of smooth muscle cell
proliferation and neointimal formation such as is found in
restenosis and transplant arteriopathies. This discovery could
potentially lead to novel therapeutic targets for the treatment of
vascular proliferative disorders.
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Supplemental Material 
Online Methods:  
Mice:  All C57/Bl6 mice (Taconic) used for pluronic applications and carotid ligation injury 
models were 10-18 week old males and ApoE-/- were 15-18 week old males.  All mice were kept 
on a standard 12 hour light/dark cycle and fed a normal chow diet.  Food and water was 
available ad-libatum.  Mice containing a heterozygous deletion of Cx43 (Cx43+/-, as described)1 
were bred to produce litters containing wild type (Cx43+/+), heterozygous (Cx43+/-) and knockout 
(Cx43-/-) newborns mice for isolation of aortic tissue.  Tail snips from each newborn mouse were 
used for genotyping and loss of Cx43 further confirmed by Western blotting.  All animals were 
used according to the University of Virginia Animal Care and Use Committee guidelines as 
previously described.2 
The Cx43 MAPK knock-in mice (Cx43-MK4A) were made using a v6.5 ES cell line 
derived from C57Bl/6J and 129S6SvEV F1 hybrid mice.  The knock-in vector contained a 5’ 
homology arm, the non-coding Exon 1, a neo/PGK cassette flanked by loxP sites followed by 
Exon2 that contains the whole Cx43 coding sequence including the mutations (S255A, S262A, 
S279A and S282A) and a 3’ homology arm.  After electroporation, ES cells were screened with 
long range PCR using primers amplifying from the homology arms to the floxed neomycin 
cassette, and homologous recombination was confirmed by Southern blotting to ensure intact 
homologous recombination into the Cx43 locus (Online Figure I).  The mice were interbred with 
B6.C-Tg (CMV-cre) 1Cgn/J mice (Jackson) to remove the neomycin selection cassette and then 
backcrossed to C57Bl/6J mice 6 times to omit the Cre gene and approach strain homogenicity.  
All mice used for experimentation were 10-18 week old males. 
Vascular smooth muscle cell (VSMC) isolation:  Newborn mice were euthanized by 
decapitation and descending aortas removed, placed into a wash solution (HBSS,1% BSA, 1% 
Glutamine, 1% sodium pyruvate, L-ascorbic acid w/v 10%w/v, pyruvate 20% w/v, Fungizone 
0.1%), and dissected horizontally and longitudinally.  Explants, were placed in 75 mm flasks 
containing 2 mL of Amniomax C-100 media plus supplement (Gibco), and incubated at 37ºC, 
5% CO2 for 2 weeks with media changed every 3 days.  After VSMC outgrowth, explants were 
removed and media replaced with fresh supplemented Amniomax media for 1 week (Online 
Figure II).  Cells were trypsinized, re-plated in the same 75mm flask (Passage 1, P1) and grown 
to near confluence.  Media was then exchanged for DMEM F12 containing 20% FBS (Defined, 
Hyclone) with 1% pen/strep, 1% glutamine for 48 hour, VSMC trypsinized and re-plated in 225 
mm flasks (P2) and grown to near confluence.  Finally media was exchanged for growth media 
(10% FBS in DMEM F12 with 1% pen/strep, 1% glutamine) for 48 hours before cells being 
trypsinized and re-plated into 225 mm flasks (P3). Cells were used between P4 and P8 for all 
experiments. 
Carotid surgeries:  Pluronic application surgeries were performed as described.2  Briefly, mice 
were anesthetized by intraperitoneal injection of ketamine-xylazine, the left common carotid 
artery exposed, and PDGF (200 ng) mixed in pluronic gel (F-127) was applied to the outside of 
the carotid wall.  Forty-eight hours after the surgery, mice were euthanized with an 
intraperitoneal injection of 60-90 mg/kg pentobarbital, mice were perfused with 4% PFA and 
both treated (left common) and control (right common) carotids removed and stored in 4% PFA 
overnight for whole mount analysis or immuno-sectioning.  For ultrastructure transmission 
electron microscopy (TEM) and immune-TEM (i-TEM) vessels were fixed in 4% PFA containing 
gluteraldehyde (2.5% or 0.5% respectively).  For in vivo cell proliferation studies, mice were pre-
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injected with 5-ethynyl-2’-deoxyuridine (EDU) prior to surgeries and carotids removed post-
treatment for whole mount analysis of EDU incorporation into VSMC (n=4, as described).2 
Carotid ligation (injury) surgeries were performed as previously described.3  Briefly, mice 
were anesthetized by intraperitoneal injection of ketamine-xylazine, the left common carotid 
artery exposed and carefully freed from surrounding tissue.  A 6/0 silk suture was run under the 
carotid artery distal to the bifurcation site and two consecutive, flat square knots were tied tight 
enough to restrict blood flow.  Control mice were surgical controls, where carotid artery was 
exposed and freed of surrounding tissue as described above, but no suture was applied.  At 2 
weeks after surgery, mice were euthanized with an intraperitoneal injection of 60-90 mg/kg 
pentobarbital, mice were then perfused with a krebs buffered solution containing heparin 
followed by 4% PFA in krebs solution.  Carotids were then removed and stored in 4% PFA 
overnight for whole mount analysis or immuno-sectioning.  We characterized neointima 
formation in C57Bl/6 mice to occur at between 1-3mm distal of the ligation site as has been 
previously described.3  For analysis of neointima formation in vessels, areas corresponding to 
the adventitia (immediately surrounding the media), the media (containing VSMC), neointima 
(containing VSMC) and lumen were measured on H&E stained cross sections of carotid vessels 
were measured using MetaMorph image analysis software (n=7, Online Figure III). 
In-vitro cell proliferation:  VSMC were plated at 5x10^4 cells in 6 well plates for 24 hours in 
growth media and cell cycle stall induced by switching to a low serum media (0.5% FBS) for 48 
hours followed by transfection with plasmids (5 µg DNA each, Cx43-/- VSMC only,) using 
Lipofectamine 2000 for 18 hours.  Cells were then incubated with EDU (5 µg/mL) with or without 
the addition of PDGF (10 ng/mL) for 24 hours in low serum media. In studies of reduced gap 
junction communication, carbenoxolone (25 M) was applied to cells for 30 mins prior to the 
addition of PDGF and EDU for 24 hours.  Cells were trypsinized, pelleted, re-suspended in 0.5 
mL PBS then fixed using 4% PFA and stored at 4°C. Cell proliferation was measured by flow 
cytometry of Alexa 488 labeled EDU as previously described.2 
Plasmids:  A DNA construct for full length rat Cx43 (Cx43, a.a.1-382,4 Online Figure IV) in 
vector pcDNA3.1 was grown in DH5α cells (Invitrogen).  In experiments, control vector was 
empty pcDNA3.1.  The Cx43 C-terminus (Cx43CT, rat, a.a. 236-382, Online Figure IV) DNA 
construct sub-cloned in frame with the glutathione S-transferase (GST) tag in pGEX-6P-2 
plasmids was kindly provided by Dr P. Sorgen (as described 5) and was grown in BL21-codon 
plus cells (Stratagene/ Agilent technologies< Santa Clara, CA).  Full length human cyclin E 
(cyclin E1, transcript variant 2, NM 057182.1) inserted in the pGEX-2T plasmid, kindly provided 
by Dr B. Lüscher,6 was transformed in BL21-codon plus cells.  All DNA sequencing was 
performed by the UVA sequencing core facility. 
Site directed mutagenesis:  Primers for site directed mutagenesis of Cx43/ Cx43CT were 
designed using QuikChange primer design program and mutagenesis performed using the 
QuikChange kit (Agilent, Stratagene, Santa Clara, CA).  Primers were designed against MAPK 
serines (Cx43: S255, S262, S279, S282 or corresponding Cx43CT: S20, S27, S44, S47), to 
alanine (non-phosphorylated, Cx43MK4A/Cx43CTMK4A) or to aspartate (phospho-mimetic, 
Cx43MK4D/ Cx43CTMK4D) See Online Figure IV.  To produce Cx43CT constructs used for 
transfection of Cx43-/- cells a stop codon was inserted immediately 5’ of a.a. 382 of the Cx43CT, 
Cx43CTMK4A and Cx43CTMK4D constructs by site directed mutagenesis.  Constructs were then 
excised using BamH1 and Xho1 from the pGEX-6P-2 vector and ligated to the pcDNA3.1 
vector.  Following mutagenesis, plasmids were sequenced using primers designed against the 
T7 promoter in the pcDNA3.1 vector and against Cx43 (for full length Cx43) or against the 
pGEX expression vector or the T7 promoter for Cx43CT plasmids.   
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Bacterial protein expression and purification:  Connexin 43CT proteins were purified as 
described,5 with the following alterations to the protocol.  Plasmids were transformed into BL21 
competent bacterial cells.  Bacterial clones grown in 2 L of LB broth were induced at 0.5 OD600 
with 1 mM isopropyl-1-thio-B-D-galactopyranoside (IPTG) for 3 hours.  Bacteria were pelleted 
and re-suspended (1 g/ 5 mL) in protein buffer: PBS (pH 7.4); NaCl (190 mM); dithiothreitol 
(DTT, 1mM); Pefabloc (0.1 mM) and complete protease inhibitor cocktail (1:100, Sigma) then 
stored at -80 °C.  Cells were thawed and membranes disrupted by microfluidics then lysates 
cleared by centrifugation (100,000 x g, 1 hour, 4°C).  Supernatants were incubated with 4 mL of 
gluthatione-sepharose beads (Glutathione-sepharose 4 fast flow, GE Lifesciences) for 3 hours, 
flow rate 0.5 mL/min at 4°C.  Protein bound beads were washed with 40 column volumes of 
protein buffer, followed by 20 column volumes of protein buffer without Pefabloc or protease 
inhibitors and GST cleavage performed by incubation with PreScission (80U) at 4°C overnight 
with rocking.  Eluted Cx43CT proteins were further purified by size exclusion (320 mL Superdex 
75 size exclusion column, GE Healthcare Bio-Sciences Corp., Piscataway, NJ) to greater than 
90% purity.  Eluted Cx43CT samples were collected and concentrated using Amicon centriplus 
10 filters.  
Cyclin E was prepared as described7 with the following modifications.  Cyclin E 
transformed BL21 bacterial cells were grown overnight then media inoculated to 0.1 OD.  
Bacteria were grown in 4 L to 1.0 OD at 37 °C, chilled to 16 °C on ice, grown at 16 °C for 1 hour 
then protein expression induced with ITPG (0.1 mM) for 24 hours at 16 °C.  Bacteria were then 
pelleted and re-suspended in protein buffer and protein purification was performed as described 
for Cx43CT proteins except cyclin E-GST was eluted from the beads (without cleavage) in a 
solution of PBS plus L-glutathione (1 mM) prior to size exclusion purification (as above). 
Analytical size exclusion chromatography (ANSEC):  Prior to analysis, sample buffers were 
altered to pH 6.5, KCl (40 mM) with no DTT using PD10 de-salting columns (GE Lifesciences) 
followed by concentration of proteins to approximately 15-20 mg/mL.  Proteins analyzed by 
ANSEC were at a final concentration of 350 µM for Cx43CT and 75 µM for cyclin E-GST with a 
molar ratio of 4.7:1 (43CT: cyclin E-GST) for combined samples.  Samples were run on a Bio-
Silect SEC 250-5 column with a bed volume of 14 mL (300x7.8 mm, Biorad; Hercules, CA) 
either as single proteins or as Cx43CT + cyclin E-GST co-incubated for 5 minutes prior to loading 
on ANSEC column.  Eluted fractions from the column were analyzed by Western Blot for the 
presence of Cx43 and cyclin E.  Molecular weight standards of blue dextran (~2,000 kDa; void 
volume), alcohol dehydrogenase (150 kDa) and albumin (66 kDa) were run using the above 
conditions and eluted in fractions 11, 16 and 17, respectively. 
Cell culture, total protein isolations:  Following treatments, all cells were harvested in cold 
lysis buffer 1: PBS (pH 7.4) containing: NaCl (125 mM); EDTA (5 mM); sodium deoxycholate 
(1%); triton X-100 (0.5%); sodium orthavanadate (500 µM); AEBSF (10 µM); protease inhibitor 
cocktail (1:100, Sigma) and phosphatase inhibitor cocktail 2 + 3 (1:100, Sigma).  All isolations 
were performed at 4 °C, samples were dounced 30 times on ice, incubated with rotation for 30 
mins at 4 °C and centrifuged at 14,000g for 5 minutes.  Cleared lysates were used for Western 
blot and co-immunoprecipitation analysis.  For experiments investigating Retinoblastoma (Rb) 
and its phosphorylation by Western blot, total protein lysates were sonicated immediately 
following harvest in lysis buffer 1 and used without centrifugation.  Proteins samples were 
-
tubulin. 
Cell culture, membrane preparations:  Membrane fractions were harvested as previously 
described.2  Briefly, following treatments all cells were harvested in lysis buffer 2: PBS (pH 7.4) 
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containing: NaCl (125 mM); sodium orthavanadate (500 µM); AEBSF (10 µM); protease inhibitor 
cocktail (1:100, Sigma) and phosphatase inhibitor cocktail 2 + 3 (1:100, Sigma).  All isolations 
were performed at 4 °C, samples were dounced 30 times on ice, incubated with rotation for 30 
mins at 4 °C and centrifuged at 14,000g for 5 minutes.  Cleared lysates were then centrifuged at 
100,000g at 4 °C for 1 hour and pellets (membrane fractions) resuspended in lysis buffer 1.  
Harvested membrane fractions were dounced 30 times on ice, incubated with rotation for 30 
mins at 4 °C and centrifuged at 14,000g for 5 minutes.  Cleared lysates were used for Western 
blot and co-immunoprecipitation analysis.  Proteins were quantified by bradfords assay prior to 
loading and equal loading confirmed on Western Blot using GAPDH as previously described for 
membrane proteins.8  Membrane sample purity was determined by through lack of detection of 
-tubulin by Western blot. 
Co-immunoprecipitation:  Vascular smooth muscle cells (Cx43+/+) were switched to low serum 
media for 72 hours prior to treatment with PDGF (10 ng/mL) for 24 hours.  The VSMC isolated 
from Cx43-/- in growth medium were transfected by Nucleofector (Lonza) using 10 µg of each 
plasmids for 18 hours followed by incubation with PDGF for 24 hours.  Following treatments all 
cells were harvested as described above for total protein lysates or membrane proteins.  
Dynabeads coated with antibodies for either Cx43, cyclin E or CDK 2 were incubated with 
lysates for 3 hours at 4 °C followed by 4 washes in lysis buffer 1 prior to elution of bound 
proteins from the beads using 5x lamelli buffer for Western Blot analysis (as described).9 
Scrape load dye transfer (SLDT):  Cells stalled were transfected (as above, using 
Lipofectamine) then treated with PDGF (10 ng/mL)
treatment (control).  Twenty four hours after treatment, lucifer yellow (0.5 mg/mL in PBS) was 
applied to cells then a scrape was created using a 23G needle, with 3 scrapes per well. After 10 
minute incubation at 37°C, cells were washed in PBS and fixed for 5 mins in 4% PFA (as 
described)10.  Images of dye transfer were captured on an Olympus FVX with a 20x 0.6 NA 
water immersion lens. Distance of dye transfer was quantified from the wound edge using 
MetaMorph imaging software. 
Cell Treatments:  For inhibition of Cx43:cyclin interactions, cell cycle stalled Cx43+/+ VSMC 
were pre-treated with Erk inhibitors, U0126 (10 µM, VWR,11 kindly provided Dr Norbert 
Leitinger) or Roscovitine (15 µM, Selleck)12 or with DMSO (1 µl/mL, control) prior to treatment 
with PDGF (10 µg/mL). 
Antibodies:  Immunocytochemistry, i-TEM and Western blot analysis of samples were 
performed using antibodies against: Cx43 (polyclonal, Sigma);2 MAPK phosphorylated-Cx43 
(Cx43-P, polyclonal);2 cyclin E (monoclonal and polyclonal Abacam);13, 14 cyclin D1 (monoclonal 
Abcam);15 p21 (monoclonal, Santa Cruz);16 p27 (monoclonal, Santa Cruz);17 CDK2 (monoclonal, 
BD biosciences);18 eNOS (polyclonal, BD biosciences);19 prolyl-4-hydroxylase (polyclonal, 
Abcam);20 SM -actin (polyclonal, sigma);21 SM-22  (polyclonal, Abcam);22 total Retinoblastoma 
(Rb clone 4H1, polclonal Cell Signaling);23 phosphorylated Rb780 (monoclonal Cell Signalling);24 
phosphorylated Rb807/811 (monoclonal, Cell Signalling).25  Antibodies were visualized with donkey 
anti-rabbit or anti-mouse Alexa 594/ Alexa 488 for immunocytochemistry or using 680/800 nm 
conjugated secondary antibodies (LI-COR) for Western blotting. 
Immunocytochemistry:  All immunofluorescence was performed as described.26  In all images 
Cx43 and cyclin E were detected using secondary antibodies coupled to Alexa 594 and Alexa 
488 respectively with nuclei identified through 4',6-diamidino-2-phenylindole (DAPI) staining.   
For quantification of pixel intensities in carotids, regions corresponding to VSMC layers were 
placed between layers of elastic lamina using MetaMorph imaging software (as described).2, 3 In 
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each image, at least three areas of VSMC were recorded; at least three images were used per 
mouse per treatment (n = 4). 
 
Transmission electron microscopy:  Carotid samples (isolated as above) were analyzed by 
TEM or i-TEM as previously described.2, 26  Analysis of protein interactions on i-TEM was 
performed using differing sized immuno-gold beads to detect: Cx43/ Cx43-P (25 nm), CDK2 (15 
nm) and cyclin E (10 nm).  To determine the distance relationship between the proteins, the 
distance between the edges of each bead type and its closest surrounding bead was measured 
using Metamorph imaging software.  An n=20 interactions was measured for each treatment 
with representative images shown. 
Statistical analysis:  1-way or 2-way ANOVA followed by Bonferroni’s post-test were used for 
comparisons between 3 treatment groups and student t-test used for comparisons of 2 
treatment groups.  A P value of <0.05 was significant, in all images * is P < 0.05, ** is P<0.01 
and *** is P< 0.001. 
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n=3 mean SE
Empty 0 0
Cx43 5.07524 0.46426
Cx43MK4D 4.37382 0.50823
Cx43MK4A 4.75226 0.8343
n=3 mean SE
Empty 0 0
Cx43 4.77667 2.33989
Cx43MK4D 4.22333 2.35404
Cx43MK4A 0 0
n=3 mean SE
Empty 0 0
Cx43 1.0063 0.50397
Cx43MK4D 1.0758 0.67533
Cx43MK4A 0 0
Cx43 Input
Cx43 IP
Ratio (IP:Input)
Online Table I
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Online Figure Legends 
Supplementary Figure I: Generation of Cx43-MK4A mice:  In A, the scheme for the knock-in 
vector highlights site of insertion of Cx43 knock in (KI) coding sequence including the mutations 
(S255A, S262A, S279A and S282A).  PCR analysis of DNA samples taken from wild type (wt), 
heterozygous and Cx43-MK4A demonstrates the slower migrating band that is seen for Cx43-
MK4A construct (B).  
Supplementary Figure II: Isolation of aortic VSMC.  Newborn mice (around 2 hours old) 
taken from breeding pairs of Cx43+/- mice were euthanized by decapitation and the descending 
aortas removed (A).  Explants were plated in supplemented Amniomax media and VSMC 
sprouting observed over a 2 week period before removal of explants and re-plating of VSMC 
(Passage 1, B).  Cells were confirmed to be VSMC by immunofluorescence based on the 
presence of SM α-actin (Red, C) with nuclei labeled using DAPI (Blue, C).  In B the scale bars 
are: top left is 200 m, top right and lower left are 50 m and in C 
isolated from newborn mouse aortas of C57Bl/6 mice were confirmed to be VSMC through the 
absence of the endothelial cell marker eNOS as shown in endothelial cells (EC, HUVEC cells), 
the absence of fibroblast marker prolyl-4-hydroxylase as shown in primary human fibroblasts 
(Fibroblast) and by the presence of smooth muscle markers SM α-actin and SM-22  (D).  
These studies identified that cells isolated from the aortas of newborn mice were primarily 
VSMC.  In D, black arrowheads identify the expected molecular weight for each protein, colored 
arrowheads correspond to molecular weights: green is 25 kDa, blue is 37 kDa, red is 50 kDa, 
Yellow is 100 kDa. 
Supplemental Figure III: Vessel wall measurements in carotid ligation mice.  Areas 
corresponding to the adventitia (A), media (M), neointima (N) and lumen (L) were measured on 
H&E sections from control and injury mice for C57Bl/6 and Cx43-MK4A mice with MetaMorph 
imaging software (A).  In A the scale bar is 100 m.  Areas were converted from pixels to mm2 
and statistical analysis performed comparing controls versus injury in C57Bl/6 and Cx43-MK4A 
mice, n=7 for each condition (B).  In C57Bl/6 mice following injury, we observed increases in 
adventitial and media thicknesses as well as the development of neointima and consequently 
reductions in lumen diameter.  In Cx43-MK4A mice, we did not observe thickening of the 
adventitial layer or significant formation of neointima (B).  However, alterations within the media 
layer were evident with an increased media thickness, which was significantly less than in 
C57Bl/6 mice (B).  In graphs, “*” indicates P<0.05 and “***” indicates P<0.001 (B, n=7)   
Supplemental Figure IV: Plasmid generation and mutagenesis.  Plasmids for full length 
Cx43 (Cx43, a.a. 1-382, pCDNA 3.1) or Cx43 C-terminus (Cx43CT, a.a. 236-382, pCDNA3.1 or 
p-GEX6P2) (A) were sequenced then mutagenesis performed to produce the phospho-mimetic 
form (Aspartate, D) or null phosphorylation forms (Alanine, A) at the MAPK serines 
representative of S255, S262, S279 and S282 in the C-terminus (B).  Amino acid regions 
highlighted in green show the known α-helical regions within the Cx43 C-terminus. 
Supplementary Figure V: Cx43 interacts with cyclin E in aortic smooth muscle cells.  
Mouse aortic VSMC (Cx43+/+) were stalled in 0.5% serum media for 72 hours followed by 24 
hours in either 0.5% or 10% serum as indicated.  Cells were lysed in lysis buffer 1 and cleared 
lysates incubated with Dynabeads coated with Cx43, cyclin E, cyclin D1, p21waf1/cip1 or p27kip1 
antibodies as labeled.  Proteins eluted from beads were analyzed by Western blot using 
antibodies directed against Cx43, cyclin D1, cyclin E, p21waf1/cip1, p27kip1.  Representative 
Western Blots (input) demonstrate that in cells treated with 10% serum, expression levels of 
Cx43, cyclin E and CDK2 are increased, whereas expression of the cell cycle inhibitors 
p21waf1/cip1, p27kip1 are decreased.  Co-Immunoprecipitation (IP) studies demonstrate that of the 
proteins tested only Cx43 and cyclin E form in complex in proliferating cells (10% serum).  Black 
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arrowheads identify the expected molecular weight for each protein, colored arrowheads 
correspond to molecular weights: green is 25kDa, blue is 37 kDa, red is 50kDa. 
Supplemental Figure VI:  PDGF promotes formation of complexes between Cx43, cyclin E 
and CDK2 in vitro.  Mouse aortic VSMC (Cx43+/+) were stalled in 0.5% serum media for 72 
hours followed by 24 hours in either 0.5% or 10 ng/mL PDGF in 0.5% serum as indicated.  Cells 
were lysed in lysis buffer 1 and cleared lysates were incubated with dynabeads coated with 
Cx43, cyclin E or CDK2 antibodies as labeled.  Proteins eluted from beads were analyzed by 
Western blot using antibodies directed against Cx43, cyclin E or CDK2.  Representative 
Western Blots (input) demonstrate that in cells treated with PDGF, expression levels of Cx43, 
cyclin E and CDK2 are increased.  Co-Immunoprecipitation (IP) studies demonstrate that Cx43, 
cyclin E and CDK2 form in complex in PDGF treated cells.  Black arrowheads identify the 
expected molecular weight for each protein, colored arrowheads correspond to molecular 
weights: green is 25kDa, blue is 37 kDa, red is 50kDa. 
Supplemental Figure VII:  Effects of transfection on gap junction communication.  
Confluent monolayers of Cx43+/+ or Cx43-/- cells in low serum were transfected with Cx43 
plasmids as described in supplemental materials and lucifer yellow dye transfer was assessed 
by SLDT in control (untreated) or PDGF treated cells (A).  In both untreated Cx43+/+ and Cx43-/- 
cells, dye transfer from the edge of the wound to surrounding cells was identified.  Transfection 
of Cx43-/- cells with plasmids containing full length Cx43 did not produce significant alterations in 
dye transfer in untreated or PDGF treated conditions (A-B).  Reductions in dye transfer were 
observed following treatments of Cx43-/- 
both untreated and PDGF treated cells (A).  In B representative images show dye transfer in 
vector transfected, CBX treated Cx43-/- cells and in untreated and PDGF treated Cx43 
transfected Cx43-/- cells.  In B the dashed line represents the edge of the scrape, scale bar is 40 
+/+ cells pre-
proliferation following treatment with PDGF as compared to PDGF treated (C).  In graphs, “*” 
indicates P<0.05 and “***” indicates P<0.001 (A, n=3 and C, n=6) 
Supplemental Figure VIII:  Expression of free Cx43CT proteins in Cx43-/- VSMC.  Mouse 
aortic VSMC (Cx43-/-) in low serum were transfected with Cx43CT plasmids as described in 
supplemental materials.  Following PDGF treatments cells were lysed in lysis buffer 1 and 
cleared lysates were incubated with dynabeads coated with cyclin E antibodies.  Proteins eluted 
from beads were analyzed by Western blot using antibodies directed against Cx43.  
Representative Western Blots (input) demonstrate that free Cx43CT, Cx43CTMK4A, Cx43CTMK4D 
proteins can be expressed in the Cx43-/- cells.  Co-Immunoprecipitation (IP) studies 
demonstrate that free Cx43CT proteins do not co-precipitate with cyclin E in PDGF treated Cx43-
/- cells (A).  VSMC proliferation was increased in Cx43-/- cells transfected to express full length 
Cx43 but not free Cx43CT, Cx43CTMK4A, Cx43CTMK4D proteins in response to PDGF treatments (B).  
Comparisons of proteins isolated form transfected Cx43-/- cells demonstrate the both full length 
and free Cx43CT proteins can be identified in total protein lysates but only full length proteins can 
be identified in the cell membranes (C).  In A and C, black arrowheads identify the expected 
molecular weight for each protein, colored arrowheads correspond to molecular weights: green 
is 25kDa, blue is 37 kDa, red is 50kDa. In graphs “***” indicates P<0.001 (B, n=4) 
Supplemental Figure IX:  Effects of PDGF treatments on cyclin E and CDK2 in Cx43-/- 
cells.  Mouse aortic VSMC (Cx43-/-) grown in low serum for 72 hours were treated with PDGF 
and harvested at specific timepoints over the course of 24 hours as described in supplemental 
materials and methods.  Cells were lysed in lysis buffer 1 and cleared protein lysates were 
analyzed by Western Blot for cyclin E an CDK2 expression.  PDGF treatments did not produce 
notable increases in cyclin E expression but CDK2 proteins were found to be increased by 24 
hours.  
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Supplemental Figure X:  Cx43 expression in Cx43-MK4A carotid VSMC. Carotid sections 
were analyzed by immunofluorescence for protein expression using antibodies directed against 
Cx43.  In each image red represents Cx43, green represents internal elastic lamina, blue 
Immunofluorescence quantification of Cx43 (B) and SM22-  (C) from carotid VSMC layers.  
Treatment of carotids with PDGF increases Cx43 expression in VSMC from C57Bl/6 but not 
Cx43-MK4A mice (n=4). 
Supplemental Figure XI:  Cx43 interactions in Cx43-MK4A carotid VSMC. Carotid sections 
from Cx43-MK4A mice were analyzed by immunofluorescence for protein expression and co-
localization using antibodies directed against Cx43, cyclin E or CDK2.  In each image red 
represents Cx43, green represents either cyclin E or CDK2 (as labeled), blue indicates nuclei 
-localization 
(orange) was detected in either control or treated vessels from Cx43-MK4A mice. 
Supplemental Figure XII:  Schematic of Cx43 phosphorylation and control of VSMC 
proliferation.  VSMC proliferation in atherogenesis is associated to increases in PDGF and 
alterations in the expression of Cx43 (A). PDGF which acts via its receptor activates an ERK 
signaling pathway that induces phosphorylation of Cx43 at the MAPK serines (B).  Following 
phosphorylation of Cx43 MAPK serines (C1), both cyclin E and CDK2 interact with the C-
terminus of Cx43 (C2).  Following interactions, the protein complex becomes internalized (C3). 
The interaction of Cx43 and cyclin E is critical in the regulation of VSMC proliferation (C4). 
Online Table I: Quantification of Cx43 expression in transfected Cx43-/- cells. Western blot 
band intensities for Cx43 protein in transfected (top) and transfected co-immunprecipitation  
(middle) samples were used to calculate a ratio (IP: Input, bottom) for each sample.  Samples 
were quantified using Licor Odyssey imaging software and analysis performed by Origin Pro 
software (n=3). 
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